Pre-specified secondary analysis (cost-effectiveness) of an RCT in 100 women with breast cancer-related lymphoedema: LVA plus CDT versus CDT alone gave an ICER of €1716/QALY (societal) and €59 679/QALY (healthcare perspective) over 2 years.
Secondary analysisn = 100
Kleeven et al. Economic evaluation of lymphaticovenous anastomosis versus conservative therapy for breast cancer-related lymphoedema: secondary outcome analysis of a randomized clinical trial